Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation
Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the efficacy and safety of lenvatinib in the treatment
of recurrence of hepatocellular carcinoma after liver transplantation.